Current Oncology | Top Cited Papers in 2022 in the Section “Health Economics”
As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top cited papers in the Section “Health Economics” shown below:
1. “The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context”
by Ivan Yanev, Jessy Gatete, Jr., Armen G. Aprikian, Jason Robert Guertin and Alice Dragomir
Curr. Oncol. 2022, 29(5), 3393–3424; https://doi.org/10.3390/curroncol29050275
Available online: https://www.mdpi.com/1718-7729/29/5/275
2. “The Pathway for New Cancer Drug Access in Canada”
by Joanna Gotfrit, William Dempster, Johanne Chambers and Paul Wheatley-Price
Curr. Oncol. 2022, 29(2), 455–464; https://doi.org/10.3390/curroncol29020041
Available online: https://www.mdpi.com/1718-7729/29/2/41
3. “Determinants of the Cancer Drug Funding Process in Canada”
by Joanna Gotfrit, Ashley Jackson, John J. W. Shin, David J. Stewart, Ranjeeta Mallick and Paul Wheatley-Price
Curr. Oncol. 2022, 29(3), 1997–2007; https://doi.org/10.3390/curroncol29030162
Available online: https://www.mdpi.com/1718-7729/29/3/162
4. “Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations”
by Louise Binder, Majd Ghadban, Christina Sit and Kathleen Barnard
Curr. Oncol. 2022, 29(3), 1514–1526; https://doi.org/10.3390/curroncol29030127
Available online: https://www.mdpi.com/1718-7729/29/3/127
5. “Challenges and Adaptations for Providing Smoking Cessation for Patients with Cancer across Canada during the COVID-19 Pandemic”
by Graham W. Warren, Caroline Silverman and Michelle Halligan
Curr. Oncol. 2022, 29(4), 2263–2271; https://doi.org/10.3390/curroncol29040184
Available online: https://www.mdpi.com/1718-7729/29/4/184
6. “Equity-Oriented Healthcare: What It Is and Why We Need It in Oncology”
by Tara C. Horrill, Annette J. Browne and Kelli I. Stajduhar
Curr. Oncol. 2022, 29(1), 186–192; https://doi.org/10.3390/curroncol29010018
Available online: https://www.mdpi.com/1718-7729/29/1/18
7. “Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status”
by Marie-France Savard, Elizabeth N. Kornaga, Adriana Matutino Kahn and Sasha Lupichuk
Curr. Oncol. 2022, 29(1), 383–391; https://doi.org/10.3390/curroncol29010034
Available online: https://www.mdpi.com/1718-7729/29/1/34
8. “Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada”
by Andrea M. Guggenbickler, Heather K. Barr, Jeffrey S. Hoch and Carolyn S. Dewa
Curr. Oncol. 2022, 29(10), 7285–7304; https://doi.org/10.3390/curroncol29100574
Available online: https://www.mdpi.com/1718-7729/29/10/574
9. “Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021”
by Catherine Lau and George Dranitsaris
Curr. Oncol. 2022, 29(11), 8031–8042; https://doi.org/10.3390/curroncol29110635
Available online: https://www.mdpi.com/1718-7729/29/11/635
10. “Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group”
by Wei Fang Dai, Claire de Oliveira, Scott Blommaert, Reka E. Pataky, David Tran, Zeb Aurangzeb, Cynthia Kendell, Chris Folkins, Chandy Somayaji, Jeff Dowden et al.
Curr. Oncol. 2022, 29(3), 2046–2063; https://doi.org/10.3390/curroncol29030165
Available online: https://www.mdpi.com/1718-7729/29/3/165